{"title": "W. Martin Kast, PhD | Keck School of Medicine of USC", "author": null, "url": "https://keck.usc.edu/faculty-search/w-martin-kast/", "hostname": "keck.usc.edu", "description": null, "sitename": "Keck School of Medicine of USC | Leaders in medical education, research and patient care", "date": "2018-07-31", "cleaned_text": "W. Martin Kast Walter A. Richter Cancer Research Chair Director Medical Biology Graduate Program University of Southern California: Graduate Student Mentoring Award, 2021 USC Stevens Center for Innovation : Commercialization Award, 2021 10XGenomics: 10XGenomics Prize, 2021 Society of Immunotherapy of Cancer: Team Science Award, 2020 University of Southern California: Dornsife Award for Exceptional Service, 2019 Affymetrix: Affymetrix Prize, 2016 STOP Cancer: STOP Cancer Award, 2015 Rare Genomics Institute: BeHeard Ultimate Prize, 2015 University of Southern California: Mellon Award for Graduate Student Mentoring, 2014 University of Amsterdam: Landsteiner Prize, 2012 IRPC: Eminent Scientist of the Year, 2010 World Scientist Forum: North American Immunologist of the Year, 2010 Royal Netherlands Academy of Arts and Sciences: Royal Netherlands Academy of Arts & Sciences Award, 1991-1995 Netherlands Cancer Institute: Antoni van Leeuwenhoek Prize, 1991 Understanding medical mistrust and HPV vaccine hesitancy among multiethnic parents in Los Angeles J Behav Med. 2023 04; 46(1-2):100-115. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35107656) Diversity Anal HPV and Non-HPV Sexually Transmitted Infections and Concordance with Genital Infections in HIV-Infected and HIV-Uninfected Women in the Tapaj\u00f3s Region, Amazon, Brazil Viruses. 2023 06 06; 15(6). . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/37376627) Examining multilevel influences on parental HPV vaccine hesitancy among multiethnic communities in Los Angeles: a qualitative analysis BMC Public Health. 2023 03 22; 23(1):545. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/36949438) Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus Cancers (Basel). 2022 Sep 05; 14(17). . immunotherapy into treatment of cervical cancer: Recent data and ongoing trials Cancer Treat Rev. 2022 05; 106:102385. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35413489) Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors Cancer Immunol Res. 2020 07; 8(7):856-868. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32295785) The Essential Role of anxA2 in Langerhans Cell Birbeck Granules Formation Cells. 2020 04 15; 9(4). . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32326440) Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) Clin Cancer View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/33154746) Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy View Immunotherapy Front Immunol. 2020; 11:922. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32499782) Therapeutic of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease Vaccine. 2019 05 16; 37(22):2915-2924. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31010714) Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study BMC Cancer. Oct View in self-collection women from Tapaj\u00f3s region, Amazon, Brazil: High acceptability, hrHPV diversity and risk capsid disassembly, and protects virions lysosomal degradation Sci 08 03; 8(1):11642. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30076379) Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response 13(1):e0191311. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30568638) Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy Oncotarget. 2017 Sep of HPV and other sexually transmitted pathogens the development [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29179876) A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression Front Immunol. 2017; 8:563. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28567040) the Human Papillomavirus 16 Capsid L2 and Is Virol. 2016 Feb; 97(2):422-434. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26555393) T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in of Papillomavirus 2:21-30. . View in Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment AIDS Patient Care STDS. 2016 07; 30(7):291-306. . on 05; 36(5):291-301. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26653678) Isoaspartylation to lung cancer-associated autoimmunity protein ELAVL4 in inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro Virol J. 2016 of HIV-Positive Patients 09 01; . View [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27149102) Current therapeutic vaccination and cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Clin cells stabilized Poly-I:C Res. 2015 Dec 01; 1:12-21. . View in A novel papillomavirus . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26044793) Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes Prostate. 2015 Feb 15; 75(3):280-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25399517) Molecular analysis of human papillomavirus virus-like particle activated in 2015; 1249:135-49. . the annexin A2 heterotetramer prevent maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression J Immunol. 2014 192(10):4748-57. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24719459) Suppression of Langerhans cell is conserved amongst human papillomavirus a and \u00df genotypes, 2014 Mar; 452-453:279-86. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24606705) The evolving field of human papillomavirus receptor research: a review of binding and entry J Virol. 2013 Jun; 87(11):6062-72. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23536685) Human papillomavirus infection in head and neck cancer: the role of in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23467841) A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies J Transl Med. 2012 Nov 05; 10:218. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23127127) Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability Int Rev Immunol. 2012 Oct; 31(5):302-20. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23083343) Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia J Pathol. 2012 Apr; treatment options for locoregionally advanced head and neck squamous cell carcinoma Int Rev Immunol. 2012 Feb; 31(1):22-42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22251006) Perspective for prophylaxis and treatment of cervical cancer: an immunological approach Int Rev Immunol. 2012 Feb; 31(1):3-21. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22251005) In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma...and more Int Rev Immunol. 2012 Feb; 31(1):1-2. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22927980) Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer Prostate. 2012 Jan; 72(1):12-23. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21652011) Cancer testis antigen, ropporin, a potential target myeloma J Immunother. 2011 Jul-Aug; inhibitor is decreased in metastatic head and cell carcinoma Int J Oncol. Jul; novel and targetable proteins cancer Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21557639) Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21557635) Bovine can detected in keratinocytes of sarcoid tumors Vet Microbiol. 2010 Dec 15; . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21095508) Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting Mol Interv. 2010 Aug; 10(4):197-203. . View in Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression Cancer Res. 2010 May 15; 70(10):3955-64. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20460520) Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer PLoS One. 2010 May 12; 5(5):e10471. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20485677) Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Group Cancer. 2010 116(2):424-31. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19918923) Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages Vaccine. 2009 Dec 30; 27 Suppl 6:G52-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20006141) A major role for the minor capsid protein of human papillomavirus type 16 in immune escape J Immunol. 2009 Nov 15; 183(10):6151-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19864613) Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck. 2009 Nov; 31(11):1393-422. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19787782) Immunogenicity of Vaccine. in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19559114) Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19789304) Sperm protein 17 is expressed in the sperm fibrous sheath J Transl Med. 2009 Jul 15; 7:61. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19604394) Prostate stem cell antigen: a prospective therapeutic and diagnostic target Cancer Lett. 2009 May 18; 277(2):126-32. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18838214) Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition Cancer Immunol Immunother. subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecol Oncol. prostate cancer vaccine immunogenicity only when applied after immunization Prostate. 2009 May 01; 69(6):571-84. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19143030) Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16 J Immunol. 2009 Mar 01; 182(5):2919-28. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19234187) of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer Viral Immunol. 2008 Dec; 21(4):435-42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19115932) Peptide-based vaccines for cancer: their potential Expert Rev Vaccines. 2008 Dec; 7(10):1533-45. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19053209) Protective CD8+ driven by rAAV/GFP/IE1 loading of cells J Transl 2008 Oct 6:56. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18834548) Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells Oncogene. 2008 Oct 02; 27(44):5833-44. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18560356) Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer J Immunother. 2008 . View in cytotoxic towards View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18004565) Sperm sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines Cancer Immun. 2008 Apr 24; 8:8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18433090) A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunol Rev. 2008 Apr; 222:316-27. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18364011) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother. 2008 Mar; cancer multiple myeloma J Haematol. 2008 Feb; 140(4):465-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18217892) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity Cancer Res. 2008 Feb 01; 68(3):861-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18245488) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions Int J Cancer. 2008 Jan 15; 122(2):247-59. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17973257) Programmed death-1 blockade enhances expansion and functional capacity of melanoma antigen-specific CTLs Int Immunol. 2007 Oct; 19(10):1223-34. A phase II study in human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity J Immunol. 2007 Jun 15; 178(12):7587-97. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17548594) Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides J Transl Med. 2007 Jun 07; 5:26. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17555571) Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17558744) The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors Vaccine. 2007 Apr 30; 25(17):3437-44. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17241713) Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax J Transl Med. 5:20. . View [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17451606) Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7 Clin Cancer Res. 2007 Apr 15; 13(8):2385-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17438097) A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17 J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17336323) Mechanisms used by human papillomaviruses to escape the host immune response Curr Cancer Drug Targets. 2007 Feb; 7(1):79-89. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17305480) In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer Cancer Res. 2007 Feb 01; 67(3):1344-51. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17283172) Therapeutic vaccination for HPV induced cervical cancers Dis Markers. 2007; 23(4):337-52. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17627067) Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant J Transl 23; 4:42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17059610) T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16374636) Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil ICAM-I molecules in multiple myeloma cell lines and primary tumors In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16759154) Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma Hum Pathol. mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro Hum Immunol. 2005 Jul; 66(7):762-72. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16112023) Vaccination Against Cervical Cancer: Hopes and Realities Am J Cancer (Auckl). 2005 Jul; 4(4):207-219. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/34566405) Human escape recognition through Langerhans cell 3-kinase activation J papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine. 2005 Feb 25; 23(14):1720-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15705478) Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor Cancer Res. 2005 Feb 15; 65(4):1570-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15735047) The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management Eur Oncol. 2005; . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15857016) Synopsis of 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy J Transl Med. 2004 Jun 22; May 15; 10(10):3301-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15161683) Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors Oncogene. 2004 May 13; 23(22):3972-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15077191) Sperm protein 17 replicon particles encoding mutated HPV16 Vaccine. 2004 Jan 02; 22(3-4):520-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/14670335) Cure of glioma: a space not yet occupied for the lesion Cancer Invest. 2004; 22(3):479-80. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15493370) Ligation established anergy of CD8+ cytolytic lymphocytes in . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12969968) Cancer immunotherapy: avoiding the perdition J Transl Med. 2004 07 29; 2(1):26. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15283862) Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes Cancer Invest. 2004; 22(3):417-34. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15493363) Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay Cancer Immunol Immunother. 2003 Oct; 52(10):655-60. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12942201) Is sperm protein 17 a useful target for tumor immunotherapy? Blood. 2003 Sep 15; 102(6):2308-9.. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12959941) Advances in prophylactic cancer Expert Rev 2003 2003 Jul 21(23):3219-27. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12804851) Differential uptake and cross-presentation human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res. 2003 Jul 01; 63(13):3478-82. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12839929) Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation Vaccine. 2003 Jun 02; 21(19-20):2506-15. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12744885) Recent progress in Expert Opin regulate Notch-1 expression and induce transformation J Cell Physiol. 2003 Mar; 194(3):356-62. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12548555) CD4+ T cell matters tumor immunity Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12962272) Advances Adv Cancer Res. 2003; 87:159-94. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12641276) Cervical clinical trials 2003 Jan 01; 8:s81-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12456298) Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002 Cancer Immunol Immunother. 2002 Dec; 51(11-12):674-6. . Oncol. 2002 14(6):641-8. of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice Cancer Res. 2002 Oct 15; 62(20):5792-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12384540) The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells J Immunol. 2002 View virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses J Immunol. 2002 Sep 15; 169(6):3242-9. . View Activation Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells Nat Med. 2002 Sep; 8(9):979-86. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12185362) Ins and outs of clinical trials with peptide-based vaccines Front Biosci. 2002 May 01; 7:e204-13. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11991853) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy J Immunother. 2002 Mar-Apr; 25(2):97-138. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12074049) Interferon-gamma reduces antigen expression and recognition of melanoma cells by cytotoxic T cells Am J Pathol. 2002 Feb; 160(2):521-8. . in . View in cell-mediated human papillomavirus-induced cervical for Adv Cancer Res. . View in of human L1 chimeric virus-like particles versus 2002; 45(4-6):300-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12566713) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci U S A. 2001 Dec . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11734652) Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines Virology. 2001 Nov 25; 290(2):350-60. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11883199) Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Res. Nov 01; 61(21):7861-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11691804) Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice Cancer Res. 2001 Aug 01; 61(15):5857-60. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11479226) Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo Cancer Res. 2001 Jul 15; 61(14):5499-504. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11454698) Pharmacokinetic differences between cell-tolerizing and a peptide J Immunol. 166(12):7151-7. . chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro J Immunol. 2001 May 15; 166(10):5917-24. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11342606) Prospect leukemia Leukemia. 2001 May; 15(5):701-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11368429) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol. 2001 May 01; 166(9):5366-73. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11313372) Physical interaction of human papillomavirus virus-like particles with immune cells Int Immunol. 2001 May; 13(5):633-41. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11312251) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells J Immunol. 2001 May 01; 166(9):5398-406. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11313376) Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen J Cell Biochem. 2001 Apr 2-27; 82(1):155-62. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11400172) Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7 Clin View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11300474) A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11300486) Tracking the common ancestry of antigenically distinct cancer variants Clin Cancer Res. 2001 . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11300485) Cervical cancer vaccines: and developments J Cell Physiol. 2001 Feb; 186(2):169-82. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11169454) Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice Virology. 2001 Jan 05; 279(1):354-60. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11145916) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical intraepithelial neoplasia who are 2000 Sep; 6(9):3406-16. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10999722) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother. 2000 Mar-Apr; 23(2):255-66. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10746552) Notch signaling Successful immunotherapy of an intraocular tumor in mice Cancer Res. 1999 Oct 15; 59(20):5250-4. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10537305) Effects of TGF-beta on the immune system: implications for cancer immunotherapy Leukemia. 1999 Aug; 13(8):1188-99. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10450746) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial Eur J Cancer. 1999 Jun; 35(6):946-52. . murine self-antigen-specific protective and therapeutic antitumor immune response J Cell 1999 May 01; 73(2):145-52. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10227378) Modulation of the immune response and tumor growth by activated Ras Leukemia. 1999 Apr; 13(4):502-13. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10214854) Induction Mar; of viral peptides to HLA-A2 allelesImplications for human papillomavirus type 16 E7 peptide-based vaccination cervical carcinoma. Eur J Immunol. 1999 04; 29(4):1292-303. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10229097) Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region Arch Virol. 1999; 144(7):1323-43. . View in and advances 1998 Dec; epitope protects type . View protection from tumor challenge elicited by HPV16 virus-like particles Virology. 1998 Oct 25; 250(2):371-6. T lymphocyte in vivo by APC 1998 Jul 15; 58(14):3094-100. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9679976) PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired J Immunother. 1998 Jul; 21(4):317-22. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9672853) Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation dendritic cells J Immunol. 1998 May 01; 160(9):4449-56. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9574550) The biological activities of simian virus 40 large-T antigen and its possible oncogenic effects in humans Monaldi Arch Chest Dis. 1998 Apr; 53(2):193-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9689808) The detection of simian virus 40 in human tumors by polymerase chain reaction Monaldi Arch Chest Dis. 1998 Apr; 53(2):202-10. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9689810) Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors Monaldi Arch Chest an HPV16 tumor model Proc Natl U S A. 1998 Feb 17; 95(4):1800-5. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9465097) Identification of peptides for immunotherapy of cancerIt is worth the effort. Crit Rev Immunol. 1998; 18(1-2):7-27. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9419444) SV40-like sequences in and . [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9776223) Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target J Immunol. 1997 Dec 01; 159(11):5545-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9548495) Activation CTL against conserved epitopes do not protect against progression to AIDS J Immunol. 1997 Oct 01; 159(7):3648-54. . View in encoded by the tumor-specific MAGE-2 gene product Int J Cancer. 1997 Sep 26; 73(1):125-30. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9334819) . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9271585) Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes Cancer Lett. 1997 Jun 03; 116(1):93-101. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9177463) The current status of therapeutic HPV vaccine Ann Med. 1996 Dec; 28(6):471-7. . View Peptide specificity of positive T lymphocytes directed against a major histocompatibility complex class I disparity Transplantation. 1996 Nov 27; 62(10):1485-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8958276) Immunotherapy of cancer by peptide-based vaccines for the induction tumor-specific T cell immunity Immunotechnology. 1996 Nov; 2(4):241-51. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9373306) Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer Clin Cancer Res. 1996 Nov; 2(11):1825-8. in antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Res. 1996 Aug 15; 56(16):3782-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8706024) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction Proc Natl Acad Sci U Jul 23; 93(15):7855-60. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8755566) Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int J Cancer. 1996 May 29; 66(5):686-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8647633) Enhanced tumor outgrowth vaccinationFunctional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996 May 15; 156(10):3911-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8621930) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability J Immunol. 1996 May 01; 156(9):3308-14. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8617954) Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive lesions against a human leukocyte in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8564975) An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cellsIdentification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum cells with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat Med. 1995 Dec; 1(12):1297-302. . View Cytotoxic T lymphocytes a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus 16-induced tumors Eur J Immunol. 1995 Sep; [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7589138) The use B lymphocyte cell lines a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):86-94. View in Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape Biochem Soc Trans. 1995 Aug; a CTL epitopes than induction of View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8537084) Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells J Exp Med. 1995 Jul 01; 182(1):163-74. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7790816) Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2 Cancer Res. 1995 15; 55(12):2627-34. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7540106) Human CTL human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides J . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7538538) T-cell of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes Rev. 1995 Jun; 145:167-77. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7590825) MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells J Immunol. 1995 Jun 01; 154(11):5715-24. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7751623) recognizing a mutated p21ras peptide presented by HLA-A*0201 Int J Cancer. 1995 May 04; 61(3):389-96. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7729952) A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding Hum Immunol. 1995 May; 43(1):13-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7558924) Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay Hum Immunol. 1995 May; 43(1):1-12. specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells J Immunol. 1995 Apr 15; 154(8):3991-8. . type region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene J Immunol. 1995 Apr 01; 154(7):3396-405. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7534797) Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect flanking sequences J Immunol. 1995 Feb 01; 154(3):1273-9. . Induction of a cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase AIDS. 1995 Feb; 9(2):121-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7536421) Class I MHC-peptide and functional implications Cancer Surv. 1995; 22:37-49. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7536628) Functional and Biol. 1995; 378:227-31. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8526062) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes J Immunol. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7527444) Efficient MHC class I-peptide binding is required but does leukemia J Virol. in T cells Immunol Lett. 1994 May; 40(2):171-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8088874) HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 Immunol. 1994 Apr 15; 152(8):3904-12. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7511661) Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):119-28. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8136944) Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and 1994; 187:97-104; discussion 104-12. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7796678) Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing Eur J Immunol. 1993 Dec; 23(12):3082-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8258321) Potential immunogenicity oncogene gene products Opin Immunol. 1993 Oct; 5(5):709-13. induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53 Eur J Immunol. 1993 Sep; 23(9):2072-7. T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur J Immunol. 1993 Sep; of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):121-6. human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother Emphasis Tumor Aug; tumor-specific cytotoxic T J cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection J Virol. 1993 Jul; 67(7):4182-9. . View in View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7684681) Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination J 1993 May; 23(5):1189-92. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8386667) The MHC expression of dendritic cells from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture 1992 Nov; 22(11):3013-20. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1425925) A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation J Immunol Methods. 1992 Oct 19; 155(1):101-11. T lymphocytes J Immunol. 1992 Jun; 22(6):1639-42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1601045) Lessons from T cell responses to virus induced tumours for cancer eradication in general Cancer Surv. 1992; 13:81-99. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1423326) Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses Eur Dec; 21(12):2963-70. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1660811) Pretransplantation blood Engl J Med. 1991 Oct 24; 325(17):1210-3. . View in In lymphocyte therapy of cancer and tumor escape mechanisms Semin Cancer 1991 Oct; 2(5):347-54. in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1754715) Peptide selection I molecules Nature. 1991 Apr 25; 350(6320):703-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1708852) Protection against lethal by in vivo priming of virus-specific peptide Proc Sci U S A. 1991 Mar 88(6):2283-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1848698) Mechanisms of transplantation tolerance: antibodies play a role? Transplant Proc. 23(1 1):155-6.. T lymphocytes directed against Suppl. 1991; 6:90-4. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2066186) Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells J Immunol. 1990 Oct 01; 145(7):2254-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2168920) Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro Cell. 1990 Aug 10; 62(3):563-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2199065) Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed J. Aug; Efficacy of cytotoxic virus-induced tumors 1990 Apr; 2(4):116-20. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2143919) Induction of transplantation intravenous injection of allogeneic lymphocytes across an H-2 class II mismatchDifferent mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity. Eur J Immunol. 1990 Feb; 20(2):441-4. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2555063) Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors Transplantation. 1989 Nov; 48(5):844-7. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2815256) Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells J Immunol. 1989 Jun 01; 142(11):4113-7. . View allograft enhancement an H-2 class-I mismatch caused by a clonal deletion of donor-specific cytotoxic T-lymphocyte precursors 54 1:597-603. . View [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2700948) Mechanism of skin allograft enhancement across an H-2 class I mutant differenceEvidence for involvement of veto cells. Eur J Immunol. 1988 Dec; 18(12):2105-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2975604) Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells May 01; 140(9):3186-93. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2834454) Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens Ann N Y Acad Sci. 1988; 532:280-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2845847) Thymic immune gene function in radiation chimeras reconstituted with purified hemopoietic stem cells Eur J Immunol. Apr; 17(4):471-5. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/3106065) Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infectionProtection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med. 1986 Sep 01; 164(3):723-38. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/3018121) Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function Immunogenetics. 1986; 24(4):267-74. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/3491042) Abolition of specific immune response defect by immunization with dendritic cells Nature. 1985 Nov 7-13; 318(6041):59-62. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2932649) Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells J Exp Med. 1984 Dec 01; 160(6):1752-66. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/6096476) Specificity and regulation of the cytotoxic lymphocyte response against Sendai "}